In this video, Motley Fool health care analyst Brenton Flynn takes a look at Celgene (NAS: CELG) and its cancer drug Abraxane. The company's shares received a boost on Monday after releasing phase 3 data showing that the drug had a statistically significant impact on survival rates for advanced pancreatic cancer. Flynn takes us through the likelihood of Abraxane getting approval from the Food and Drug Administration, the growth potential in the market for this drug if it is approved, and what that could mean for this company's future.
Celgene's story is a very compelling one for investors to be following at the moment as this drug grows into its full potential on the market. While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Celgene Hits the Mark With Abraxane originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.